You are here

  • Home
  • Archive
  • Volume 82, Issue 4
  • Response to: ‘Correspondence on ‘Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden’’ by Zervou et al

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Correspondence on ‘Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden’’ by Zervou et al
Free
  1. Viktor Molander1,2,
  2. Johan Askling1,2
  1. 1 Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden
  2. 2 Rheumatology, Karolinska University Hospital, Stockholm, Sweden
  1. Correspondence to Dr Viktor Molander, Clinical Epidemiology Division, Karolinska Institutet, 171 77 Solna, Sweden; viktor.molander{at}ki.se

https://doi.org/10.1136/annrheumdis-2021-219920

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank the authors for their interest1 in our article ‘Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden’2, and for their effort in identifying genetic factors involved in the pathogenesis of both rheumatoid arthritis (RA) and venous thromboembolism (VTE).

    As the authors suggest, identification of additional genetic loci associated with both diseases would be another important step in understanding the reasons behind the increased VTE risk in RA and might also help in identifying patients at particularly increased risk of VTE.

    Ethics statements

    Patient consent for publication

    References

    1. ↵
      2. Zervou MI ,
      3. Goulielmos GN
      . Correspondence on “Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden.” Ann Rheum Dis 2023;82:e87. doi:10.1136/annrheumdis-2021-219894
    2. ↵
      2. Molander V ,
      3. Bower H ,
      4. Frisell T , et al
      . Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis 2021;80:169–75.doi:10.1136/annrheumdis-2020-218419 pmid:http://www.ncbi.nlm.nih.gov/pubmed/33032998
      OpenUrlAbstract/FREE Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors VM and JA contributed to the drafting of the response.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests Karolinska Institutet, with JA as principal investigator, has or has had research agreements with Abbvie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB, mainly in the context of safety monitoring of biologics via ARTIS/Swedish Biologics Register.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles